Results 131 to 140 of about 329,027 (236)

Engineering antibodies with cancer‐associated binding sites

BMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian, Yumeng Pan, Yingchun Zhang, Fangling Wang, Zejun Wang   +4 more
wiley   +1 more source

Designing next‐generation immune cell therapies with nanomaterials

BMEMat, EarlyView.
Nanomaterials are transforming immune cellular therapies (ICT) by addressing challenges like tumor accessibility and lengthy manufacturing. This perspective highlights innovations such as magnetic nanoparticles for target identification, lipid nanoparticles for T cell stimulation, and nanoparticle‐mediated gene cytokine delivery. These advances promise
Kangfu Chen, Wenhan Wang, Zongjie Wang
wiley   +1 more source

Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages

Cancer Communications, EarlyView.
Abstract Background Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM.
Rongrong Zhao, Ziwen Pan, Jiawei Qiu, Boyan Li, Yanhua Qi, Zijie Gao, Wei Qiu, Weijie Tang, Xiaofan Guo, Lin Deng, Gang Li, Hao Xue   +11 more
wiley   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson III, Hye Sung Kim, Liam Il‐Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock   +16 more
wiley   +1 more source

Immunosuppressive JAG2+ tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells

Cancer Communications, EarlyView.
Abstract Background Tumor‐associated neutrophils (TANs) play a critical role in modulating immune responses and exhibit significant heterogeneity. Our previous study demonstrated that jagged canonical Notch ligand 2 (JAG2)+ TANs were associated with an immunosuppressive microenvironment in high‐grade serous ovarian cancer (HGSOC), but the underlying ...
Chenyang Wang, Moran Yang, Yujing Zhong, Kankan Cao, Xueling Wang, Chen Zhang, Yiying Wang, Mengdi He, Jiaqi Lu, Guodong Zhang, Yan Huang, Haiou Liu   +11 more
wiley   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

Fibrotic Fortresses and Therapeutic Frontiers: Pancreatic Stellate Cells and the Extracellular Matrix in Pancreatic Cancer. [PDF]

Cancer Med
Sigirli S, Karakas D.
europepmc   +1 more source

Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

Cancer Communications, EarlyView.
Abstract Background Pancreatic cancer's aberrant lipid metabolism fuels cell growth, invasion, and metastasis, yet its impact on immune surveillance and immunotherapy is unclear. This study investigated how sterol regulatory element‐binding transcription factor 1 (SREBP1)‐driven lipid metabolism affects the tumor microenvironment (TME) in pancreatic ...
Mengyi Lao, Xiaozhen Zhang, Zejun Li, Kang Sun, Hanshen Yang, Sicheng Wang, Lihong He, Yan Chen, Hanjia Zhang, Jiatao Shi, Daqian Xu, Tingbo Liang, Xueli Bai   +12 more
wiley   +1 more source

Electron Transport Bilayer Design for Perovskite‐Based Tandem Solar Cells Using Thermal Evaporation

Chemistry–Methods, EarlyView.
We provide a comprehensive explanation of designing a bi‐layer electron transport layer with a fullerene layer using the evaporation method in inverted perovskite solar cells (PSCs) and perovskite‐based tandem solar cells (PTSCs). Furthermore, we provide candidate materials for a bi‐layer and suggest a fullerene/SnO2 bi‐layer configuration for high ...
Siwon Yun, Hyeji Han, Muhammad Adnan, Wonjong Lee, Min Kim, Jongchul Lim, Jinseck Kim   +6 more
wiley   +1 more source

Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
Although attractive for relevance to real‐world scenarios, real‐world data (RWD) is typically used for drug repurposing and not therapeutic target discovery. Repurposing studies have identified few effective options in neurological diseases such as the rare disease, amyotrophic lateral sclerosis (ALS), which has no disease‐modifying treatments ...
Mohammadali Alidoost, Jeremy Y. Huang, Georgia Dermentzaki, Anna S. Blazier, Giorgio Gaglia, Timothy R. Hammond, Francesca Frau, Mary Clare McCorry, Dimitry Ofengeim, Jennifer L. Wilson   +9 more
wiley   +1 more source